Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053319 · ClinicalTrials.gov registry record · Phase 1
SGLT2i, Pioglitazone, and Ketone Production in T2D
A Phase 1 study of Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT07053319: Recruiting Phase 1 study of Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
NCT07053319 is a Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053319, a Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Primary Outcome
Measurement of Endogenous Glucose Production (EGP) using stable isotope (6,6, D2- glucose infusion).
Conditions Studied
Interventions
- DRUG Empagliflozin 25 MG plus Pioglitazone placebo
- DRUG Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo
- DRUG Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- DRUG Pioglitazone placebo + Empagliflozin placebo
Study Locations (1)
Texas
- Texas Diabetes Institute/UH - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT07053319 shows while recruiting
NCT07053319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which Empagliflozin 25 MG plus Pioglitazone placebo is the first listed.
NCT07053319 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07053319 about?
NCT07053319 is a clinical study titled "SGLT2i, Pioglitazone, and Ketone Production in T2D". To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
What is the current status of trial NCT07053319?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2026-07-20. Estimated completion is 2027-06-30.
What conditions does trial NCT07053319 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT07053319?
The interventions under investigation include: Empagliflozin 25 MG plus Pioglitazone placebo (DRUG), Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo (DRUG), Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) (DRUG), Pioglitazone placebo + Empagliflozin placebo (DRUG).
Who is sponsoring clinical trial NCT07053319?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053319 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07053319's enrollment target sits among peer trials
64 190th of 327 higher than 137 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
-
SGLTi, Hepatic Glucose Production and Ketogenesis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI